Heart failure & cardiomyopathies
Low Blood Pressure and the Effect of Empagliflozin in Acute Heart Failure: An EMPULSE Analysis
Authors' conclusion
Patients admitted for AHF with low BP had a higher risk of clinical events. Empagliflozin did not lower BP more than placebo and was effective and safe irrespective of BP.
Study context
- Population
- Patients with acute HF, by low blood pressure (BP) (systolic BP (SBP) <110 mmHg or diastolic BP (DBP) <70 mmHg) at randomisation; SBP ≥100 mmHg required
- Participants
- 530 patients
- Comparison
- Empagliflozin vs placebo, by BP at randomisation
- Primary endpoint
- Hierarchical composite of:
- All-cause mortality
- HF events
- KCCQ total symptom score change
- Follow-up
- 90 days
Primary result
As reported in the abstract
Primary outcome, overall and by DBP at randomisation
Empagliflozin vs PlaceboWin ratio (95% CI)P value
Overall
1.48(1.15–1.90)
P = 0.0025DBP ≥70 mmHg
1.23(0.94–1.60)
DBP < 70 mmHg
2.11(1.46–3.04)
Further findings
Prevalence of low BP at randomisation
- SBP <110 mmHg
- 131 (25%)
- DBP <70 mmHg
- 190 (36%)
Prognosis of low BP (Placebo)
- Low BP associated with more clinical and adverse events in placebo
Safety
BP change with empagliflozin vs placebo · 90 days
- Small BP changes, not statistically significant
- −2 to 2 mmHg
- Patients with low BP increased BP on average over follow-up, regardless of treatment group
Original publication
Low Blood Pressure and the Effect of Empagliflozin in Acute Heart Failure: An EMPULSE Analysis. Eur J Heart Fail. Published 20 February 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →